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ObjetivOs: Caracterizar as políticas públicas de saúde no Brasil, com enfoque 
no envelhecimento populacional, na perspectiva histórica, econômica e constitu-
cional. MétOdOs: Revisão bibliográfica, retrospectiva, descritiva e comparativa de 
políticas públicas de saúde voltada aos idosos. A abordagem temporal se estende de 
1930 até a atualidade. ResultAdOs: O estudo evidenciou que as políticas públicas 
de saúde acompanham a trajetória econômica vigente do país, centradas temporal-
mente nos interesses econômicos: atividade agroexportadora (até 1930), processo 
de industrialização (1930-1990) e abertura econômica (1990-atual). Vinculam-se 
as políticas de saúde, sequencialmente, à erradicação das epidemias, principal-
mente, nas áreas portuárias, proteção do trabalhador urbano sob modelo excludente 
visando apenas aqueles inseridos no sistema formal de trabalho e, finalmente, 
a saúde como direito universal com a promulgação da Constituição Federal de 
1988. Nesse último período, estabeleceu-se o marco legal dos direitos dos idosos. A 
década de1990 e anos 2000 destacam-se pelas leis que amparam a pessoa idosa, tais 
como: a LOS – nº 8.080/1990, a LOAS / 1993; a Política Nacional da Assistência Social 
/2004; a Política Nacional do Idoso / 1994; o Estatuto do Idoso/2003; Pacto pela Vida 
/ 2006; a Política Nacional de Saúde da Pessoa Idosa/ 2006 e a resolução nomeada 
com Tipificação Nacional dos Serviços Socioassistenciais /2009. No período atual, 
o Brasil passa por processo de transição demográfica e epidemiológica devido ao 
aumento da expectativa de vida dos indivíduos; a redução do índice de natalidade 
e de mortalidade; a mudança do perfil demográfico e epidemiológico. Tais fatores 
contribuíram para o crescimento da demanda por serviços de saúde. COnClusões: 
Em período anterior a 1988 não se evidenciavam políticas públicas legais de proteção 
aos idosos. Observou-se que diversas ações de prevenção e promoção da saúde 
foram adotadas, principalmente em termos da legislação, após a Constituição de 
1988, visando garantir proteção social aos idosos.
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ObjeCtives: To assess the knowledge and practice with respect to use of medi-
cines, among post-graduate pharmacy students. MethOds: This cross-sectional 
study was carried out among the post-graduate students of NIPER, Mohali, during 
the period of Nov. 2014 to Feb. 2015. The method of data collection was based on 
pre-designed questionnaire containing close ended questions. Participants were 
randomly selected. Questionnaire inquired about their knowledge with respect to 
medicine, attitude and practising behaviour. Reponses received during the study 
period were coded and analysed using SPSS. Results: A total of 200 students 
responded to the study. All the respondents were postgraduates in the age group 
of 20-30 years. About 95% respondents completed their dosage regimen as pre-
scribed. Almost all the respondents (86%) said that they always shake the cough 
syrup bottle before use. Almost a three-quarter respondents asked the prescriber 
or dispenser about the possible side-effects of the prescribed medication. Majority 
(94%) of the respondents practised self-medication. Most common reasons for 
practising self-medication was found to be convenience (37.5%) followed by quick 
relief (25%), time saving (15%), economical (8.5%) and others (14%). 71% of the 
respondents reported the habits of sharing medicine with others. High preva-
lence (91%), of unused medication was reported. Most common reason cited for 
unused medication was discontinuation of medicines when patients start feeling 
better. COnClusiOns: The result of this study reflects a high prevalence rate of 
self-medication and unused medication. This needs to be addressed appropri-
ately. Promotion of rational use of medicine is important to achieve the required 
effectiveness of the medicines.
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ObjeCtives: The present study analyses the impact and influence of negative 
symptoms on quality of life (QoL). MethOds: The W-SOHO study is a three year 
follow-up study on the outpatient care of schizophrenia that included 17,384 
patients from 37 countries. Patients were recruited in W-SOHO by their treating 
psychiatrists when starting or changing antipsychotic medication. Evaluation 
was conducted during the normal course of care and was scheduled every six 
months after the baseline visit. The Clinical Global Impressions Severity Scale 
– Schizophrenia version (CGI-SCH) was used to assess symptom severity across 
overall, positive, negative, depressive and cognitive subdomains. Quality of life 
(QoL) was assessed using the EuroQOL 5-D questionnaire. Pearson correlation 
coefficients (PCC) were used to analyze the relationship between continuous vari-
ables. A mixed model with repeated measures (MMRM) was used to analyze the 
factors associated with quality of life during follow-up. Results: Quality of life at 
baseline was more highly correlated with negative symptoms than with positive 
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ObjetivOs: Avaliar a eficácia e segurança do ibuprofeno vs. demais anti-
inflamatórios não esteroidais, no tratamento de recém-nascidos prematuros com 
persistência do canal arterial. MétOdOs: Após elaborar a pergunta estruturada, 
a busca nas bases de dados MEDLINE, Cochrane Library, Tripdatabase, e CRD, foi 
realizada em 08/02/2015, utilizando os descritores MeSH (“Ductus Arteriosus, 
Patent”[Mesh]) AND (“Anti-Inflammatory Agents, Non-Steroidal”[Mesh]) AND 
(systematic[sb]) e seguiu as diretrizes de Avaliação de Tecnologias em Saúde 
do Ministério da Saúde. Foram identificadas 98 referências, após o processo de 
seleção norteado pela pergunta estruturada e pelos critérios de qualidade descri-
tos no instrumento AMSTAR, 6 referências relataram algum processo sistemático 
de recuperação de evidências. ResultAdOs: O risco relativo (RR) de alcançar o 
fechamento da persistência do canal arterial não apresentou diferença significativa 
entre o tratamento com ibuprofeno intravenos (IV)vs. indometacina (IV) (RR = 1; IC 
95% = 0.93–1.08). Quando comparado o ibuprofeno oral vs. indometacina oral ou 
IV, também não houve diferença estatisticamente significativa (RR = 0,96; IC 95% = 
0.73–1.27). Já quando comparado, ibuprofeno oral vs. (IV), o risco de falha no fecha-
mento da persistência do canal arterial foi 59% menor no grupo oral (RR = 0,41; IC 
95% = 0.27–0,64). Os resultados demonstram ainda uma menor tendência dos casos 
de enterocolite necrosante ao usar ibuprofeno oral. COnClusões: Ao comparar 
ibuprofeno (IV) vs. indometacina (IV), é necessário avaliar outros parâmetros para 
auxiliar na tomada de decisão. O ibuprofeno oral parece ser uma alternativa eficaz 
e segura, nos casos em que o intravenoso esta indisponível devido às diferentes 
restrições.
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ObjeCtives: Turkish Healthcare System under transformation since 2002 called 
“Health Transformation Programme’’. One of the key point regarding those changes 
is the introduction of “brand-generic drugs substitution”, in terms of the health 
and economic impact for the healthcare system. Primary concern is the mini-
mization of health expenses with satisfied health outcomes, for this countries 
need to eliminate unnecessary spending on medicines related prescribing and 
pricing within affordable limits for each stakeholder. The aims of this study are to 
show generic drug use of Turkey and marketshare of generics in pharmaceutical 
market of Turkey. We will focus on marketshares of generics and original drugs 
between the years 2008-2013 MethOds: Data of generic and original drugs sales 
percentage taken from Turkish Medical Devices and Medicines Agency report pub-
lished in 2014. Report data comprise of IMS data and indicated the years between 
2008-2013. Results: It has found that sales value of generic drugs increased 
from 33,5% to 36,2% from the years 2008 to 2013. In same period original drugs 
sales value decreased from 66,5% to 63,8%. In same period box sales of generics 
increased 24% while original drugs box sales increased %23. Despite of generic 
box sales increased 1% more than original box sales. It shown that price settings 
effects generic drugs more than original drugs during the period 2008-2013. On 
the other hand we can predict that drugs sales has close relation with drug price 
settings. Turkey is using internal and external reference pricing system since 
2004. COnClusiOns: Turkey has been processing “Health Transformation System’’ 
(HTP) since 2002. Drugs price settings was one of important key change is this 
programme. Drugs sales may affected from price setting. Drug usage increased 
as a result of HTP. Further studies needed to understand relationship between 
price settings and drug usage.
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ObjeCtives: The objective of this study is to assess the characteristics of relapsing 
remitting multiple sclerosis (RRMS) patients taking disease modifying therapies 
(DMTs) in the US. MethOds: A large US administrative retrospective claims data-
base was used to identify patients diagnosed with RRMS and were prescribed DMTs 
between January 2010 to December 2012 were included in the study. All patients 
were ≤ 17 years of age and continuously enrolled in the same health plan for a year. 
Descriptive statistics and chi-square tests were performed on the data. Results: 
There were a total of 359 patients that met the study inclusion criteria. The mean 
age of the patients was 14.19 ± 2.29 years, 61.6% of the patients were females, and 
majority of the patients were between 12 and 17 years of age (85.5%). Thirty three 
percent of the patients were from East, 20.1% were from Midwest, 36.2% from South 
and 10.6% is from West region. 59.6% of the patients were on a group coverage plan 
and 49.3% of the patients were on a DMT prescription that is under their health 
plan formulary. Majority of the patients (95%) were prescribed 30 days’ supply of 
DMTs, 1.7% were on 60 days’ supply and 3.3% were on 90 days’ supply of DMTs. More 
than half of the patients (53.8%) were diagnosed with mental health problems in 
addition to their RRMS as a primary diagnosis. On average, patients were continu-
ously enrolled for 5.10 ± 1.74 years and submitting around 466 claims during this 
period. COnClusiOns: The majority of the pediatric patients were teenagers and 
females. One third of the patients was from south and received on average a 30 
days’ supply of DMT.
